Lexaria Bioscience Corp reports results for the quarter ended November 30 - Earnings Summary

Lexaria Bioscience

10/01/2025 22:01

* Lexaria Bioscience Corp  LEXX.OQ  reported a quarterly
adjusted
loss of 16 cents​​ per share for the quarter ended November 30,
lower than the same quarter last year, when the company reported
EPS of -13 cents.  The lone analyst forecast for the quarter was
for a loss of 12 cents per share. 
    * Revenue was $183.92 thousand​; analysts expected $100.00
thousand. 
    * Lexaria Bioscience Corp's reported EPS for the quarter was
a
loss of 16 cents​.
    * Lexaria Bioscience Corp shares had risen by 5.2% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 33.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Lexaria
Bioscience Corp is $10.00 
This summary was machine generated from LSEG data January 10 at
10:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Nov. 30 2024      -0.12          -0.16          Missed
 Aug. 31 2024      -0.11          -0.14          Missed
 May. 31 2024      -0.10          -0.13          Missed
 Feb. 29 2024      -0.10          -0.06          Beat